EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rea...

2026-03-17

EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 is a highly selective DOT1L inhibitor (IC₅₀ = 0.8 nM, K_i = 80 pM) that competitively occupies the S-adenosyl methionine (SAM) binding pocket of DOT1L, inducing conformational changes that block H3K79 methylation (APExBIO). This compound demonstrates >37,000-fold selectivity over other methyltransferases and produces complete tumor regression in MV4-11 xenograft models at 35–70 mg/kg/day IV dosing for 21 days without significant toxicity (Anbazhagan et al. 2024). EPZ5676 is used primarily in biochemical assays and leukemia cell line studies, where it shows antiproliferative effects at 3.5 nM (4–7 days exposure). Its robust solubility in DMSO and ethanol, but not water, and recommended storage at −20°C are critical for workflow reliability. APExBIO supplies EPZ5676 as the A4166 kit, supporting reproducible epigenetic regulation research in oncology and beyond.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is a histone methyltransferase that catalyzes methylation at lysine 79 of histone H3 (H3K79). Aberrant H3K79 methylation is implicated in the pathogenesis of MLL-rearranged (KMT2A-rearranged) leukemia, where MLL fusion proteins recruit DOT1L to target genes, driving leukemogenic gene expression (Anbazhagan et al. 2024). Inhibition of DOT1L-mediated H3K79 methylation leads to downregulation of critical MLL-fusion target genes and halts proliferation in sensitive leukemia models. EPZ5676, provided by APExBIO, is designed for maximal selectivity, thereby minimizing off-target effects on other methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, and SMYD2/3. This selectivity profile is essential for dissecting the roles of DOT1L in epigenetic regulation in cancer and for developing targeted therapies in leukemias with poor prognosis.
For a broader mechanistic perspective, see DOT1L Inhibition as a Transformative Strategy: Mechanistic Insights, which this article extends by providing new quantitative selectivity benchmarks and in vivo results.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 functions as a SAM-competitive inhibitor. It binds the SAM pocket of the DOT1L active site, causing a conformational change that exposes a hydrophobic pocket, thus blocking substrate methylation activity. The compound's IC₅₀ is 0.8 nM toward DOT1L, and its K_i is 80 pM. Selectivity studies confirm >37,000-fold lower inhibition for other histone methyltransferases. In leukemia models with MLL fusion genes, EPZ5676 reduces H3K79 methylation and downregulates the expression of leukemogenic genes such as HOXA9 and MEIS1. The result is strong antiproliferative and pro-apoptotic effects in vitro and tumor regression in vivo. The compound does not inhibit non-DOT1L methyltransferases at concentrations up to 30 μM, supporting its use as a precision tool for histone methyltransferase inhibition assays (APExBIO).

Evidence & Benchmarks

EPZ5676 inhibits DOT1L with an IC₅₀ of 0.8 nM and a K_i of 80 pM in biochemical assays (APExBIO).
Displays >37,000-fold selectivity over CARM1, EHMT1/2, EZH1/2, PRMT family, SETD7, SMYD2/3, and WHSC1/1L1 at up to 30 μM (APExBIO).
Induces potent cytotoxicity in MLL-rearranged acute leukemia cell lines (e.g., MV4-11) with a 3.5 nM IC₅₀ after 4–7 days exposure (APExBIO).
In nude rat MV4-11 xenograft models, 21-day IV dosing at 35–70 mg/kg/day results in complete tumor regression with no significant weight loss or toxicity (Anbazhagan et al. 2024).
H3K79 methylation is reduced and MLL-fusion target gene expression is downregulated upon treatment, confirmed by Western blot and RT-qPCR (Anbazhagan et al. 2024).

This article updates the practical workflow evidence found in EPZ5676: Potent DOT1L Inhibitor for MLL-Rearranged Leukemia by providing extended selectivity data and in vivo efficacy benchmarks.

Applications, Limits & Misconceptions

EPZ5676 is primarily used in:

Histone methyltransferase inhibition assays for DOT1L specificity.
Cell proliferation and viability studies in MLL-rearranged leukemia models.
Preclinical in vivo studies of leukemia progression and regression.
Epigenetic regulation research in both oncology and developmental biology.

Common Pitfalls or Misconceptions

EPZ5676 is NOT active against other methyltransferases such as EZH2 or PRMTs at relevant concentrations; off-target effects in these families are negligible (APExBIO).
It is NOT water-soluble; solubilization must be done in DMSO or ethanol, with ultrasonic assistance for ethanol (APExBIO).
Prolonged storage of solutions at room temperature reduces activity; storage at −20°C is required for both powder and stock solutions (APExBIO).
EPZ5676 has not demonstrated efficacy in non-MLL-rearranged leukemia or solid tumors; its primary indication is for MLL/KMT2A fusion gene-driven leukemias (Anbazhagan et al. 2024).
Usage in clinical settings remains investigational; all current evidence is preclinical.

For troubleshooting and advanced protocol guidance, see EPZ5676: Potent DOT1L Inhibitor Workflows for Leukemia Research, which this article extends with updated selectivity and in vivo benchmarks.

Workflow Integration & Parameters

Solubility: ≥28.15 mg/mL in DMSO, ≥50.3 mg/mL in ethanol (with ultrasonic assistance), insoluble in water.
Recommended Storage: −20°C for solid; DMSO stock solutions stable below −20°C for several months.
Assay Use: Biochemical DOT1L enzyme inhibition, cell proliferation in MV4-11 or other MLL-rearranged cell lines.
In vivo Use: IV dosing in animal models (35–70 mg/kg/day for 21 days).
Readouts: H3K79 methylation (Western blot), target gene expression (RT-qPCR), cytotoxicity (viability assays).

Parameters for Reliable Use:

Strictly avoid long-term storage of working solutions at room temperature.
Confirm compound integrity by mass spectrometry before use in critical assays.
Use controls for other methyltransferases to validate selectivity in new systems.

Conclusion & Outlook

EPZ5676 (A4166) from APExBIO sets the benchmark for potent and selective inhibition of DOT1L, supporting both mechanistic studies and preclinical research in MLL-rearranged leukemia. Its robust selectivity, reproducible in vivo efficacy, and well-defined physicochemical profile make it a preferred tool for dissecting histone methyltransferase function in cancer epigenetics. Future research may extend its applications to other diseases linked to aberrant H3K79 methylation, pending further validation. For product details and ordering, visit the DOT1L inhibitor EPZ-5676 product page.